The Invokana® (Invokamet) lawsuit alleges that the manufacturers and marketers of SGLT2 inhibitors (such as Johnson & Johnson, Janssen Pharmaceuticals Inc., AstraZeneca & Boehringer Ingelheim) failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues and ketoacidosis.
The lawsuits provide that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes, and certainly would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.
Invokana® (Invokamet) is a SGLT2 inhibitor used in combination with diet and exercise to improve glycemic control and lower blood sugar in adults with type 2 diabetes mellitus. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve damage, kidney failure, heart disease, stroke, high blood pressure, and a range of other problems. Diabetes is the seventh leading cause of death in the U.S. SGLT2 inhibitors lower a person's blood sugar by causing the kidneys to remove it through the urine.
Canagliflozin and Metformin
Dapagliflozin and Metformin extended-release
Empagliflozin and Linagliptin
Kidney failure occurs when your kidneys stop functioning without the use of dialysis or a kidney transplant. Kidneys help filter waste products from the blood. They are also involved in regulating blood pressure, electrolyte balance, and red blood cell production. When your kidneys stop properly functioning, waste products, fluids, and electrolytes build up in the body and can cause weakness, shortness of breath, lethargy, confusion, abnormal heart rhythms and sudden death.
Myocardial infarction (commonly known as a heart attack) is the irreversible death of cells within the heart caused by a restriction of blood. It occurs when there is a blockage in the arteries preventing blood from reaching portions of the heart, and thus oxygen and necessary nutrients no longer reach the heart muscle. Basically a portion of the heart is being starved of oxygen and nutrients, a condition called "cardiac ischemia." If this condition lasts too long, the starved heart tissue dies.
Ketoacidosis is a medical condition where high levels of ketones are produced in the body. Ketoacidosis can result in a patient suffering a diabetic coma, extended hospitalization and even death. Ketoacidosis develops when the body is unable to produce enough insulin, which insulin plays a major role in helping sugar (glucose) enter cells, and provides needed energy to the muscles and other tissues. Without enough insulin, the body breaks down fat as an alternative source of energy, which process produces a buildup of toxic acids in the bloodstream called ketones. Excess ketones result in ketoacidosis if untreated.
If you are currently taking Invokana® (Invokamet) or another SGLT2 inhibitor (such as Farxiga®, Xigduo XR®, Jardiance® or Glyxambia®), you should pay close attention for any signs of kidney failure, heart problems and acidosis and seek immediate medical attention if you experience symptoms such as chest pain, dizziness, faintness, increased heart rate, increased pulmonary rate, difficulty breathing, hyperventilation, weakness, changes in urination, anorexia, nausea, vomiting, abdominal pain, confusion, lethargy and unusual fatigue or sleepiness. Do not stop or change your diabetes medicines without first talking to your medical provider, but be especially careful to take appropriate measures to monitor for signs of kidney issues, heart problems and acidosis, and immediately seek appropriate medical care if you have any concerns.
If you believe you have a CLAIM against the manufacturers of INVOKANA®, call now for a free evaluation! 205.54.7500